Genmab's Rina-S shows 45.9% response rate in ovarian cancer trial

October 3, 2026 3:40 PM

Genmab A/S (Nasdaq: GMAB) reported Phase 2 results from Part C of its RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S), an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found